Reaching the threshold: A multilayer pathogenesis of macrophage activation syndrome

Journal of Rheumatology

Volumn 40, Issue 6, 2013, Pages 761-767

  Strippoli, Raffaele ^a   Caiello, Ivan ^a   De Benedetti, Fabrizio ^a  

^a BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

Author keywords

Etiology; Hemophagocytic Lymphohistiocytoses; Juvenile Idiopathic Arthritis; Macrophage Activation Syndrome

Indexed keywords

CD163 ANTIGEN; CD34 ANTIGEN; GAMMA INTERFERON; INTERFERON REGULATORY FACTOR 5; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 18; INTERLEUKIN 6; MEMBRANE PROTEIN; PERFORIN; TOLL LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR ALPHA;

ANTIGEN PRESENTING CELL; CD8+ T LYMPHOCYTE; CELL FUNCTION; CLINICAL FEATURE; CPG ISLAND; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DISEASE ACTIVITY; DISEASE ASSOCIATION; EPSTEIN BARR VIRUS; EXPERIMENTAL MODEL; GENE DELETION; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; HEMOPHAGOCYTIC SYNDROME; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOPATHOLOGY; IMMUNOREGULATION; JUVENILE RHEUMATOID ARTHRITIS; LIVER BIOPSY; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MACROPHAGE; MACROPHAGE ACTIVATING SYNDROME; MOLECULARLY TARGETED THERAPY; NATURAL KILLER CELL; NONHUMAN; PATHOGENESIS; PRIMARY HEMOPHAGOCYTIC SYNDROME; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SALMONELLA ENTERICA; SECONDARY HEMOPHAGOCYTIC SYNDROME; SEQUENCE HOMOLOGY; TRANSGENIC MOUSE; TYPHOID FEVER;

ETIOLOGY; HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSES; JUVENILE IDIOPATHIC ARTHRITIS; MACROPHAGE ACTIVATION SYNDROME;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; INFLAMMATION; MACROPHAGE ACTIVATION; MACROPHAGE ACTIVATION SYNDROME; MICE; RHEUMATIC DISEASES;

EID: 84878666042     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.121233     Document Type: Review

References (50)

1. Ravelli A. Macrophage activation syndrome. Curr Opin Rheumatol 2002;14:548-52.
2. Behrens EM. Macrophage activation syndrome in rheumatic disease: What is the role of the antigen presenting cell? Autoimmun Rev 2008;7:305-8.
3. Grom AA, Mellins ED. Macrophage activation syndrome: Advances towards understanding pathogenesis. Curr Opin Rheumatol 2010;22:561-6.
4. Risma K, Jordan MB. Hemophagocytic lymphohistiocytosis: Updates and evolving concepts. Curr Opin Pediatr 2012;24:9-15.
5. Freeman HR, Ramanan AV. Review of haemophagocytic lymphohistiocytosis. Arch Dis Child 2011;96:688-93.
6. Jordan MB, Hildeman D, Kappler J, Marrack P. An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8+ T cells and interferon gamma are essential for the disorder. Blood 2004;104:735-43.
7. Crozat K, Hoebe K, Ugolini S, Hong NA, Janssen E, Rutschmann S, et al. Jinx, an MCMV susceptibility phenotype caused by disruption of Unc13d: A mouse model of type 3 familial hemophagocytic lymphohistiocytosis. J Exp Med 2007;204:853-63.
8. Pachlopnik Schmid J, Ho CH, Chretien F, Lefebvre JM, Pivert G, Kosco-Vilbois M, et al. Neutralization of IFN-gamma defeats haemophagocytosis in LCMV-infected perforin- and Rab27a-deficient mice. EMBO Mol Med 2009;1:112-24.
9. Lykens JE, Terrell CE, Zoller EE, Risma K, Jordan MB. Perforin is a critical physiologic regulator of T-cell activation. Blood 2011;118:618-26.
10. Jessen B, Maul-Pavicic A, Ufheil H, Vraetz T, Enders A, Lehmberg K, et al. Subtle differences in CTL cytotoxicity determine susceptibility to hemophagocytic lymphohistiocytosis in mice and humans with Chediak-Higashi syndrome. Blood 2011;118:4620-9.
11. Chen M, Felix K, Wang J. Critical role for perforin and Fas-dependent killing of dendritic cells in the control of inflammation. Blood 2012;119:127-36.
12. Yang J, Huck SP, McHugh RS, Hermans IF, Ronchese F. Perforin-dependent elimination of dendritic cells regulates the expansion of antigen-specific CD8+ T cells in vivo. Proc Natl Acad Sci USA 2006;103:147-52.
13. Tang Y, Xu X, Song H, Yang S, Shi S, Wei J, et al. Early diagnostic and prognostic significance of a specific Th1/Th2 cytokine pattern in children with haemophagocytic syndrome. Br J Haematol 2008;143:84-91.
14. Maruyama J, Inokuma S. Cytokine profiles of macrophage activation syndrome associated with rheumatic diseases. J Rheumatol 2010;37:967-73.
15. Henter JI, Horne A, Arico M, Egeler RM, Filipovich AH, Imashuku S, et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 2007;48:124-31.
16. Sato K, Misawa N, Nie C, Satou Y, Iwakiri D, Matsuoka, M, et al. A novel animal model of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in humanized mice. Blood 2011;117:5663-73.
17. Brown DE, McCoy MW, Pilonieta MC, Nix RN, Detweiler CS. Chronic murine typhoid fever is a natural model of secondary hemophagocytic lymphohistiocytosis. PLoS One 2010;5:e9441.
18. Behrens EM, Canna SW, Slade K, Rao S, Kreiger PA, Paessler M, et al. Repeated TLR9 stimulation results in macrophage activation syndrome-like disease in mice. J Clin Invest 2011;121:2264-77.
19. Strippoli R, Carvello F, Scianaro R, De Pasquale L, Vivarelli M, Petrini S, et al. Amplification of the response to Toll-like receptor ligands by prolonged exposure to interleukin-6 in mice: Implication for the pathogenesis of macrophage activation syndrome. Arthritis Rheum 2012;64:1680-8.
20. De Benedetti F, Massa M, Robbioni P, Ravelli A, Burgio GR, Martini A. Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis. Arthritis Rheum 1991;34:1158-63.
21. Billiau AD, Roskams T, Van Damme-Lombaerts R, Matthys P, Wouters C. Macrophage activation syndrome: Characteristic findings on liver biopsy illustrating the key role of activated, IFN-gamma-producing lymphocytes and IL-6- and TNF-alpha-producing macrophages. Blood 2005;105:1648-51.
22. Shimozato O, Ortaldo JR, Komschlies KL, Young HA. Impaired NK cell development in an IFN-gamma transgenic mouse: Aberrantly expressed IFN-gamma enhances hematopoietic stem cell apoptosis and affects NK cell differentiation. J Immunol 2002;168:1746-52.
23. Villanueva J, Lee S, Giannini EH, Graham TB, Passo MH, Filipovich A, et al. Natural killer cell dysfunction is a distinguishing feature of systemic onset juvenile rheumatoid arthritis and macrophage activation syndrome. Arthritis Res Ther 2005;7:R30-7.
24. Vastert SJ, Van Wijk R, D'Urbano LE, De Vooght K, De Jager W, Ravelli A, et al. Mutations in the perforin gene may be linked to macrophage activation syndrome in patients with systemic-onset juvenile idiopathic arthritis. Rhematology 2010;49:441-9.
25. Grom AA, Villanueva J, Lee S, Goldmuntz EA, Passo MH, Filipovich A. Natural killer cell dysfunction in patients with systemic-onset juvenile rheumatoid arthritis and macrophage activation syndrome. J Pediatr 2003;142:292-6.
26. De Jager W, Vastert SJ, Beekman JM, Wulffraat NM, Kuis W, Coffer PJ, et al. Defective phosphorylation of interleukin-18 receptor beta causes impaired natural killer cell function in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 2009;60:2782-93.
27. Shibatomi K, Ida H, Yamasaki S, Nakashima T, Origuchi T, Kawakami A, et al. A novel role for interleukin-18 in human natural killer cell death: High serum levels and low natural killer cell numbers in patients with systemic autoimmune diseases. Arthritis Rheum 2001;44:884-92.
28. Schindler H, Lutz MB, Rollinghoff M, Bogdan C. The production of IFN-gamma by IL-12/IL-18-activated macrophages requires STAT4 signaling and is inhibited by IL-4. J Immunol 2001;166:3075-82.
29. van Dommelen SL, Sumaria N, Schreiber RD, Scalzo AA, Smyth MJ, Degli-Esposti MA. Perforin and granzymes have distinct roles in defensive immunity and immunopathology. Immunity 2006;25:835-48.
30. Martinez FO, Sica A, Mantovani A, Locati M. Macrophage activation and polarization. Front Biosci 2008;13:453-61.
31. De Benedetti F, Brunner HI, Ruperto N, Kenwright A, Wright S, Calvo I, et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med 2012;367:2385-95.
32. Shigemura T, Yamazaki T, Hara Y, Ou JN, Stevens AM, Ochs HD, et al. Monitoring serum IL-18 levels is useful for treatment of a patient with systemic juvenile idiopathic arthritis complicated by macrophage activation syndrome. Pediatr Rheumatol Online J 2011;9:15.
33. Shimizu M, Yokoyama T, Yamada K, Kaneda H, Wada H, Wada T, et al. Distinct cytokine profiles of systemic-onset juvenile idiopathic arthritis-associated macrophage activation syndrome with particular emphasis on the role of interleukin-18 in its pathogenesis. Rheumatology 2010;49:1645-53.
34. Zhang K, Biroschak J, Glass DN, Thompson SD, Finkel T, Passo MH, et al. Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis is associated with MUNC13-4 polymorphisms. Arthritis Rheum 2008;58:2892-6.
35. Yanagimachi M, Naruto T, Miyamae T, Hara T, Kikuchi M, Hara R, et al. Association of IRF5 polymorphisms with susceptibility to macrophage activation syndrome in patients with juvenile idiopathic arthritis. J Rheumatol 2011;38:769-74.
36. Heikenwalder M, Polymenidou M, Junt T, Sigurdson C, Wagner H, Akira S, et al. Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration. Nat Med 2004;10:187-92.
37. Savage E, Wazir T, Drake M, Cuthbert M, Wright G. Treatment of fulminant myocarditis and macrophage activation syndrome secondary to adult onset Still's disease. Abstract 2012.
38. Pascual V, Allantaz F, Arce E, Punaro M, Banchereau J. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med 2005;201:1479-86.
39. Barnes MG, Grom AA, Thompson SD, Griffin TA, Pavlidis P, Itert L, et al. Subtype-specific peripheral blood gene expression profiles in recent-onset juvenile idiopathic arthritis. Arthritis Rheum 2009;60:2102-12.
40. Quartier P, Allantaz F, Cimaz R, Pillet P, Messiaen C, Bardin C, et al. A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis 2011;70:747-54.
41. Miettunen PM, Narendran A, Jayanthan A, Behrens EM, Cron RQ. Successful treatment of severe paediatric rheumatic disease-associated macrophage activation syndrome with interleukin-1 inhibition following conventional immunosuppressive therapy: Case series with 12 patients. Rheumatology 2011;50:417-9.
42. Ravelli A, Grom AA, Behrens EM, Cron RQ. Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: Diagnosis, genetics, pathophysiology and treatment. Genes Immun 2012;13:289-98.
43. Nigrovic PA, Mannion M, Prince FH, Zeft A, Rabinovich CE, van Rossum MA, et al. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: Report of forty-six patients from an international multicenter series. Arthritis Rheum 2011;63:545-55.
44. Krebs P, Crozat K, Popkin D, Oldstone MB, Beutler B. Disruption of MyD88 signaling suppresses hemophagocytic lymphohistiocytosis in mice. Blood 2011;117:6582-8.
45. Sironi M, Breviario F, Proserpio P, Biondi A, Vecchi A, Van Damme J, et al. IL-1 stimulates IL-6 production in endothelial cells. J Immunol 1989;142:549-53.
46. Elias JA, Lentz V. IL-1 and tumor necrosis factor synergistically stimulate fibroblast IL-6 production and stabilize IL-6 messenger RNA. J Immunol 1990;145:161-6.
47. Schindler R, Mancilla J, Endres S, Ghorbani R, Clark SC, Dinarello CA. Correlations and interactions in the production of interleukin-6 (IL-6), IL-1, and tumor necrosis factor (TNF) in human blood mononuclear cells: IL-6 suppresses IL-1 and TNF. Blood 1990;75:40-7.
48. Dinarello CA. IL-1: discoveries, controversies and future directions. Eur J Immunol 2010;40:599-606.
49. Zoller EE, Lykens JE, Terrell CE, Aliberti J, Filipovich AH, Henson PM, et al. Hemophagocytosis causes a consumptive anemia of inflammation. J Exp Med 2011;208:1203-14.
50. Mazodier K, Marin V, Novick D, Farnarier C, Robitail S, Schleinitz N, et al. Severe imbalance of IL-18/IL-18BP in patients with secondary hemophagocytic syndrome. Blood 2005;106:3483-9.